<DOC>
	<DOC>NCT01971164</DOC>
	<brief_summary>The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of sequential ascending doses of JTZ-951 administered for 15 days in anemic subjects with end-stage renal disease (ESRD) receiving hemodialysis.</brief_summary>
	<brief_title>Safety, Tolerability, PK &amp; PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<criteria>Subjects who have ESRD and have been receiving maintenance hemodialysis for at least 12 weeks prior to the Screening Visit Body weight (postdialysis weight) greater than 45.0 kg and a body mass index between 20.0 and 40.0 kg/m2 (inclusive) at the Screening Visit Hemoglobin value as defined in the protocol Meet the erythropoiesisstimulating agent (ESA) therapy criteria at the Screening Visit as defined in the protocol Transferrin saturation and ferritin levels at the Screening Visit as defined in the protocol Anemia due to known causes other than chronic kidney disease Known history of hyporesponsiveness to ESAs Acute coronary syndrome (e.g., myocardial infarction) within 1 year prior to Screening visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>hemodialysis</keyword>
</DOC>